Evidence map›Paper›PMID 38641196›Full record

ArticleExperimental eye research2024

Dexamethasone sodium phosphate loaded nanoparticles for prevention of nitrogen mustard induced corneal injury.

Sagun Poudel, Ehsan Kaffash, Long Zhao, Rudra Pangeni, Woon Nam Chow, Qingguo Xu

Open access · greenAbstract read
In one paragraph

Article in Experimental eye research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
7.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Fenofibrate microemulsion eyedrops for treating nitrogen mustard induced corneal injury.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sagun PoudelDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA.
Ehsan KaffashDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA.
Long ZhaoDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA.
Rudra PangeniDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA.
Woon Nam ChowDepartment of Ophthalmology, Virginia Commonwealth University, Richmond, VA 23298, USA; Department of Pathology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Qingguo XuDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA; Department of Ophthalmology, Virginia Commonwealth University, Richmond, VA 23298, USA; Center for Pharmaceutical Engineering, and Institute for Structural Biology, Drug Discovery & Development (ISB3D), Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA. Electronic address: qxu@vcu.edu.
Virginia Commonwealth University · US

Funding

Sustained release of fenofibrate for the treatment of diabetic retinopathyR01EY033477 · NEI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Jian-Xing Jay Ma, QINGGUO XU · 2022 to 2026
$2.7M
New method to treat or prevent corneal graft rejectionR01EY027827 · NEI · VIRGINIA COMMONWEALTH UNIVERSITY · PI XU, QINGGUO · 2017 to 2021
$2.0M
NEI NIH HHS R01 EY027827NEI NIH HHS R01 EY033477
6 · The paper itself

Abstract

Nitrogen mustard (NM) is a potent vesicating chemical warfare agent that is primarily absorbed through skin, inhalation, or ocular surface. Ocular exposure of NM can cause acute to chronic keratopathy which can eventually lead to blindness. There is a current lack of effective countermeasures against ocular exposure of NM despite their imperative need. Herein, we aim to explore the sustained effect of Dexamethasone sodium phosphate (DSP)-loaded polymeric nanoparticles (PLGA-DSP-NP) following a single subconjunctival injection in the management and prevention of corneal injury progression upon exposure to NM. DSP is an FDA approved corticosteroid with proven anti-inflammatory properties. We formulated PLGA-DSP-NP with zinc chelation ion bridging method using PLGA polymer, with particles of approximately 250 nm and a drug loading of 6.5 wt%. Under in vitro sink conditions, PLGA-DSP-NP exhibited a sustained drug release for two weeks. Notably, in NM injured cornea, a single subconjunctival (SCT) injection of PLGA-DSP-NP outperformed DSP eyedrops (0.1%), DSP solution, placebo NP, and saline, significantly mitigating corneal neovascularization, ulceration, and opacity for the two weeks study period. Through PLGA-DSP-NP injection, sustained DSP release hindered inflammatory cytokine recruitment, angiogenic factors, and endothelial cell proliferation in the cornea. This strategy presents a promising localized corticosteroid delivery system to effectively combat NM-induced corneal injury, offering insights into managing vesicant exposure.

Indexed as

DexamethasoneMechlorethamineNanoparticlesAnimalsBurns, ChemicalChemical Warfare AgentsCorneaCorneal InjuriesDisease Models, AnimalEye BurnsGlucocorticoidsMiceRabbitsChemical Warfare AgentsDexamethasonedexamethasone 21-phosphateGlucocorticoidsMechlorethamineCorticosteroidsDexamethasoneOcular injuryPLGASubconjunctival injectionVesicants

Identifiers

PMID38641196
PMCPMC11184523
OpenAlexW4394929916

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.